The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The Discovery of Tadalafil: A Novel and Highly Selective PDE5 Inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1‘,2‘:1,6]pyrido[3,4-b]indole-1,4-dione Analogues
Open accessAbstract
Modification of the hydantoin ring in the previously described lead compound 2a has led to the discovery of compound 12a, tadalafil, a highly potent and highly selective PDE5 inhibitor. The replacement of the hydantoin in compound 2a by a piperazinedione ring led to compound cis-11a which showed similar PDE5 inhibitory potency. Introduction of a 3,4-methylenedioxy substitution on the phenyl ring in position 6 led to a potent PDE5 inhibitor cis-11c with increased cellular potency. Optimization of the chain on the piperazinedione ring led to the identification of the racemic cis-N-methyl derivative 11i. High diastereospecificity for PDE5 inhibition was observed in the piperazinedione series with the cis-(6R,12aR) enantiomer displaying the highest PDE5 inhibitory activity. The piperazinedione 12a, tadalafil (GF196960), has been identified as a highly potent PDE5 inhibitor (IC(50) = 5 nM) with high selectivity for PDE5 vs PDE1-4 and PDE6. Compound 12a displays 85-fold greater selectivity vs PDE6 than sildenafil 1. 12a showed profound and long-lasting blood pressure lowering activity (30 mmHg/>7 h) in the spontaneously hypertensive rat model after oral administration (5 mg/kg).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rajfer, J., Aronson, W. J., Bush, P. A., Dorey, F. J., & Ignarro, L. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260203 · Cited by 1,006
Terrett, N. K., Bell, A. S., Brown, D., & Ellis, P. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00323-x · Cited by 607
Kotera, J., Yanaka, N., Fujishige, K., Imai, Y., Akatsuka, H., Ishizuka, T., Kawashima, K., & Omori, K. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-1-00434.x · Cited by 89
Characterization of a novel potent and specific inhibitor of type v phosphodiesterase
Coste, H., & Grondin, P. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02031-4 · Cited by 62
Self-citationCartledge, J. J., & Ian Eardley, C. (1999) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.1.137 · Cited by 18
Cited by
A review on recent developments of indole-containing antiviral agents
Zhang, M.-Z., Chen, Q., & Yang, G.-F. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.065 · Cited by 887
2,5-Diketopiperazines: Synthesis, Reactions, Medicinal Chemistry, and Bioactive Natural Products
Borthwick, A. D. (2012) · Chemical Reviews · doi:10.1021/cr200398y · Cited by 880
Lugnier, C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.07.003 · Cited by 870
Puzzo, D., Staniszewski, A., Deng, S. X., Privitera, L., Leznik, E., Liu, S., Zhang, H., Feng, Y., Palmeri, A., Landry, D. W., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0864-09.2009 · Cited by 331
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Gold from the sea: Marine compounds as inhibitors of the hallmarks of cancer
Schumacher, M., Kelkel, M., Dicato, M., & Diederich, M. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.02.002 · Cited by 138
Ogasawara, D., Konrad, D. B., Tan, Z. Y., Carey, K. L., Luo, J., Won, S. J., Li, H., Carter, T. R., DeMeester, K. E., Njomen, E., et al. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.10.005 · Cited by 31
Metadata
- Authors
- Daugan, A., Grondin, P., Ruault, C., Le Monnier de Gouville, A.-C., Coste, H., Linget, J. M., Kirilovsky, J., Hyafil, F., & Labaudinière, R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2003-09-17
- Volume
- 46
- Issue
- 21
- Pages
- 4533-4542
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2001083144
- Cited by
- 282
- References
- 5
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.